organization · Reporting owner
Venrock Partners VII, L.P.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Shockwave Medical, Inc.SWAV · Entity 90374 | 10% owner | March 11, 2019 | March 13, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Shockwave Medical, Inc.
Report date March 11, 2019 · Filed March 13, 2019
Jointly reported with Venrock Associates VII, L.P., Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Management VII, LLC, Shah Nimish P, Koh Bong Y, VHCP Management II, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Funds | 2,122,021 |
Last balance in matching sequence
After 2019-03-11 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2019-03-11 · Conversion · Acquired 1,105,529 · Balance 1,105,529 F1: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F4: Venrock Management VII, LLC ("VM7") is the sole general partner of Venrock Associates VII, L.P. ("VA7") and Venrock Partners VII, L.P. ("VP7") and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA7 and VP7 except to the extent of its indirect pecuniary interest therein. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP2") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-Invest 2"), may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of its indirect pecuniary interest therein. Bong Koh and Nimish Shah are the managing members of VHCP Management II, LLC. Drs. Koh and Shah expressly disclaim beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of their indirect pecuniary interests therein. Row 2 · 2019-03-11 · Conversion · Acquired 1,016,492 · Balance 2,122,021 F1: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F4: Venrock Management VII, LLC ("VM7") is the sole general partner of Venrock Associates VII, L.P. ("VA7") and Venrock Partners VII, L.P. ("VP7") and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA7 and VP7 except to the extent of its indirect pecuniary interest therein. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP2") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-Invest 2"), may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of its indirect pecuniary interest therein. Bong Koh and Nimish Shah are the managing members of VHCP Management II, LLC. Drs. Koh and Shah expressly disclaim beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of their indirect pecuniary interests therein. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Funds | 0 |
Reported balance
After 2019-03-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-03-11 · Conversion · Acquired 1,105,529 · Balance 0 F1: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F2: Consists of 745,139 shares of convertible preferred stock held by Venrock Associates VII, L.P., 212,500 shares of convertible preferred stock held by Venrock Healthcare Capital Partners II, L.P., 61,725 shares of convertible preferred stock held by Venrock Partners VII, L.P. and 86,165 shares of convertible preferred stock held by VHCP Co-Investment Holdings II, LLC. F4: Venrock Management VII, LLC ("VM7") is the sole general partner of Venrock Associates VII, L.P. ("VA7") and Venrock Partners VII, L.P. ("VP7") and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA7 and VP7 except to the extent of its indirect pecuniary interest therein. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP2") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-Invest 2"), may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of its indirect pecuniary interest therein. Bong Koh and Nimish Shah are the managing members of VHCP Management II, LLC. Drs. Koh and Shah expressly disclaim beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of their indirect pecuniary interests therein. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Funds | 0 |
Reported balance
After 2019-03-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-03-11 · Conversion · Acquired 1,016,492 · Balance 0 F1: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F3: Consists of 382,238 shares of convertible preferred stock held by Venrock Associates VII, L.P., 428,744 shares of convertible preferred stock held by Venrock Healthcare Capital Partners II, L.P., 31,663 shares of convertible preferred stock held by Venrock Partners VII, L.P. and 173,847 shares of convertible preferred stock held by VHCP Co-Investment Holdings II, LLC. F4: Venrock Management VII, LLC ("VM7") is the sole general partner of Venrock Associates VII, L.P. ("VA7") and Venrock Partners VII, L.P. ("VP7") and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA7 and VP7 except to the extent of its indirect pecuniary interest therein. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP2") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-Invest 2"), may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of its indirect pecuniary interest therein. Bong Koh and Nimish Shah are the managing members of VHCP Management II, LLC. Drs. Koh and Shah expressly disclaim beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of their indirect pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date.
F2: Consists of 745,139 shares of convertible preferred stock held by Venrock Associates VII, L.P., 212,500 shares of convertible preferred stock held by Venrock Healthcare Capital Partners II, L.P., 61,725 shares of convertible preferred stock held by Venrock Partners VII, L.P. and 86,165 shares of convertible preferred stock held by VHCP Co-Investment Holdings II, LLC.
F3: Consists of 382,238 shares of convertible preferred stock held by Venrock Associates VII, L.P., 428,744 shares of convertible preferred stock held by Venrock Healthcare Capital Partners II, L.P., 31,663 shares of convertible preferred stock held by Venrock Partners VII, L.P. and 173,847 shares of convertible preferred stock held by VHCP Co-Investment Holdings II, LLC.
F4: Venrock Management VII, LLC ("VM7") is the sole general partner of Venrock Associates VII, L.P. ("VA7") and Venrock Partners VII, L.P. ("VP7") and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA7 and VP7 except to the extent of its indirect pecuniary interest therein. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP2") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-Invest 2"), may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of its indirect pecuniary interest therein. Bong Koh and Nimish Shah are the managing members of VHCP Management II, LLC. Drs. Koh and Shah expressly disclaim beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of their indirect pecuniary interests therein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cyteir Therapeutics, Inc.
Report date June 22, 2021 · Filed June 23, 2021
Jointly reported with Venrock Associates VII, L.P., Venrock Management VII, LLC
Section 16 reporting ended · disclosed 2021-06-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Funds | 3,259,025 |
Reported balance
After 2021-06-22 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-06-22 · Conversion · Acquired 3,259,025 · Balance 3,259,025 F1: Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 1:3.4088 upon completion of the Issuer's initial public offering. The shares have no expiration date. F2: Consists of 3,009,710 shares of Common Stock held by Venrock Associates VII, L.P. ("VA VII") and 249,315 shares of Common Stock held by Venrock Partners VII, L.P. ("VP VII"). Venrock Management VII, LLC ("VM VII") is the sole general partner of VA VII and VP VII and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA VII and VP VII except to the extent of its indirect pecuniary interest therein. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-06-22 · Conversion · Disposed 10,000,000 · Balance 0 F1: Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 1:3.4088 upon completion of the Issuer's initial public offering. The shares have no expiration date. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-06-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-06-22 · Conversion · Disposed 1,109,368 · Balance 0 F1: Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 1:3.4088 upon completion of the Issuer's initial public offering. The shares have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 1:3.4088 upon completion of the Issuer's initial public offering. The shares have no expiration date.
F2: Consists of 3,009,710 shares of Common Stock held by Venrock Associates VII, L.P. ("VA VII") and 249,315 shares of Common Stock held by Venrock Partners VII, L.P. ("VP VII"). Venrock Management VII, LLC ("VM VII") is the sole general partner of VA VII and VP VII and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA VII and VP VII except to the extent of its indirect pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2021 Filed Jun 23, 2021 16:08 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | ConversionSeries C Convertible Preferred Stock · Derivative | 1,109,368 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-042724 · doc4.xml · derivative · entry 3 Venrock Associates VII, L.P. · CIK 0001614766 · 10% owner Venrock Partners VII, L.P. · CIK 0001614765 · 10% owner Venrock Management VII, LLC · CIK 0001614686 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 325,442 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 1:3.4088 upon completion of the Issuer's initial public offering. The shares have no expiration date. F1 · price: Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 1:3.4088 upon completion of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 1:3.4088 upon completion of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 1:3.4088 upon completion of the Issuer's initial public offering. The shares have no expiration date. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 16:08 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | ConversionSeries B Convertible Preferred Stock · Derivative | 10,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-042724 · doc4.xml · derivative · entry 2 Venrock Associates VII, L.P. · CIK 0001614766 · 10% owner Venrock Partners VII, L.P. · CIK 0001614765 · 10% owner Venrock Management VII, LLC · CIK 0001614686 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,933,583 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 1:3.4088 upon completion of the Issuer's initial public offering. The shares have no expiration date. F1 · price: Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 1:3.4088 upon completion of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 1:3.4088 upon completion of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 1:3.4088 upon completion of the Issuer's initial public offering. The shares have no expiration date. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 16:08 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | ConversionCommon Stock | 3,259,025 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-042724 · doc4.xml · nonDerivative · entry 1 Venrock Associates VII, L.P. · CIK 0001614766 · 10% owner Venrock Partners VII, L.P. · CIK 0001614765 · 10% owner Venrock Management VII, LLC · CIK 0001614686 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 3,259,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 1:3.4088 upon completion of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: Consists of 3,009,710 shares of Common Stock held by Venrock Associates VII, L.P. ("VA VII") and 249,315 shares of Common Stock held by Venrock Partners VII, L.P. ("VP VII"). Venrock Management VII, LLC ("VM VII") is the sole general partner of VA VII and VP VII and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA VII and VP VII except to the extent of its indirect pecuniary interest therein. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 20:31 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | ConversionSeries C Convertible Preferred Stock · Derivative | 1,016,492 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-19-003374 · dp103684_4-venrock.xml · derivative · entry 4 Venrock Associates VII, L.P. · CIK 0001614766 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner Venrock Partners VII, L.P. · CIK 0001614765 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner Venrock Management VII, LLC · CIK 0001614686 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 0 Underlying: Common Stock · 1,016,492 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F3 · shares: Consists of 382,238 shares of convertible preferred stock held by Venrock Associates VII, L.P., 428,744 shares of convertible preferred stock held by Venrock Healthcare Capital Partners II, L.P., 31,663 shares of convertible preferred stock held by Venrock Partners VII, L.P. and 173,847 shares of convertible preferred stock held by VHCP Co-Investment Holdings II, LLC. F1 · price: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F1 · derivative.exercise_date: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F1 · derivative.expiration_date: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F3 · derivative.underlying_shares: Consists of 382,238 shares of convertible preferred stock held by Venrock Associates VII, L.P., 428,744 shares of convertible preferred stock held by Venrock Healthcare Capital Partners II, L.P., 31,663 shares of convertible preferred stock held by Venrock Partners VII, L.P. and 173,847 shares of convertible preferred stock held by VHCP Co-Investment Holdings II, LLC. F4 · ownership.nature: Venrock Management VII, LLC ("VM7") is the sole general partner of Venrock Associates VII, L.P. ("VA7") and Venrock Partners VII, L.P. ("VP7") and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA7 and VP7 except to the extent of its indirect pecuniary interest therein. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP2") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-Invest 2"), may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of its indirect pecuniary interest therein. Bong Koh and Nimish Shah are the managing members of VHCP Management II, LLC. Drs. Koh and Shah expressly disclaim beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of their indirect pecuniary interests therein. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 20:31 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,105,529 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-19-003374 · dp103684_4-venrock.xml · derivative · entry 3 Venrock Associates VII, L.P. · CIK 0001614766 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner Venrock Partners VII, L.P. · CIK 0001614765 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner Venrock Management VII, LLC · CIK 0001614686 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 0 Underlying: Common Stock · 1,105,529 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F2 · shares: Consists of 745,139 shares of convertible preferred stock held by Venrock Associates VII, L.P., 212,500 shares of convertible preferred stock held by Venrock Healthcare Capital Partners II, L.P., 61,725 shares of convertible preferred stock held by Venrock Partners VII, L.P. and 86,165 shares of convertible preferred stock held by VHCP Co-Investment Holdings II, LLC. F1 · price: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F1 · derivative.exercise_date: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F1 · derivative.expiration_date: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F2 · derivative.underlying_shares: Consists of 745,139 shares of convertible preferred stock held by Venrock Associates VII, L.P., 212,500 shares of convertible preferred stock held by Venrock Healthcare Capital Partners II, L.P., 61,725 shares of convertible preferred stock held by Venrock Partners VII, L.P. and 86,165 shares of convertible preferred stock held by VHCP Co-Investment Holdings II, LLC. F4 · ownership.nature: Venrock Management VII, LLC ("VM7") is the sole general partner of Venrock Associates VII, L.P. ("VA7") and Venrock Partners VII, L.P. ("VP7") and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA7 and VP7 except to the extent of its indirect pecuniary interest therein. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP2") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-Invest 2"), may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of its indirect pecuniary interest therein. Bong Koh and Nimish Shah are the managing members of VHCP Management II, LLC. Drs. Koh and Shah expressly disclaim beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of their indirect pecuniary interests therein. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 20:31 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | ConversionCommon Stock | 1,016,492 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-19-003374 · dp103684_4-venrock.xml · nonDerivative · entry 2 Venrock Associates VII, L.P. · CIK 0001614766 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner Venrock Partners VII, L.P. · CIK 0001614765 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner Venrock Management VII, LLC · CIK 0001614686 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 2,122,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F4 · ownership.nature: Venrock Management VII, LLC ("VM7") is the sole general partner of Venrock Associates VII, L.P. ("VA7") and Venrock Partners VII, L.P. ("VP7") and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA7 and VP7 except to the extent of its indirect pecuniary interest therein. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP2") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-Invest 2"), may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of its indirect pecuniary interest therein. Bong Koh and Nimish Shah are the managing members of VHCP Management II, LLC. Drs. Koh and Shah expressly disclaim beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of their indirect pecuniary interests therein. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 20:31 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | ConversionCommon Stock | 1,105,529 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-19-003374 · dp103684_4-venrock.xml · nonDerivative · entry 1 Venrock Associates VII, L.P. · CIK 0001614766 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner Venrock Partners VII, L.P. · CIK 0001614765 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner Venrock Management VII, LLC · CIK 0001614686 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 1,105,529 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F4 · ownership.nature: Venrock Management VII, LLC ("VM7") is the sole general partner of Venrock Associates VII, L.P. ("VA7") and Venrock Partners VII, L.P. ("VP7") and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA7 and VP7 except to the extent of its indirect pecuniary interest therein. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP2") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-Invest 2"), may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of its indirect pecuniary interest therein. Bong Koh and Nimish Shah are the managing members of VHCP Management II, LLC. Drs. Koh and Shah expressly disclaim beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of their indirect pecuniary interests therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.